Lehetôségek és eredmények a Taxol®- Herceptin® kombináció alkalmazásával

Translated title of the contribution: Possibilities and results with Herceptin®-Taxol® combination in the treatment of breast cancer

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Taxol® (paclitaxel) and Herceptin® (trastuzumab) are two milestones in the treatment of metastatic breast cancer. Accordingly it was feasible to study the combination of these two highly active drugs (with different toxicity profiles and mechanisms of action) in the treatment of metastatic breast cancer. In multicentric phase III trial performed in the US the combination of Herceptin with either taxane or anthracyclin was investigated. It was established that the combination of Herceptin with Taxol treatment significantly improves the overall response rate, increases the time to progression and the overall survival. These effects are more pronounced in patients characterized with HER/2 +++ overexpression. Based on these evidences the Herceptin®- Taxol® combined treatment protocol was introduced in Hungary for the treatment of Stage IV breast cancer patients. Láng I. Possibilities and results with Herceptin®-Taxol® combination in the treatment of breast cancer. Hungarian Oncology 46:195-196, 2002.

Original languageHungarian
Pages (from-to)195-196
Number of pages2
JournalMagyar Onkologia
Volume46
Issue number2
Publication statusPublished - 2002

Fingerprint

Paclitaxel
Breast Neoplasms
Therapeutics
Hungary
Clinical Protocols
Trastuzumab
Survival
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Lehetôségek és eredmények a Taxol®- Herceptin® kombináció alkalmazásával. / Láng, I.

In: Magyar Onkologia, Vol. 46, No. 2, 2002, p. 195-196.

Research output: Contribution to journalArticle

@article{a4bd7843304d46cbbfa4b783d0759020,
title = "Lehet{\^o}s{\'e}gek {\'e}s eredm{\'e}nyek a Taxol{\circledR}- Herceptin{\circledR} kombin{\'a}ci{\'o} alkalmaz{\'a}s{\'a}val",
abstract = "Taxol{\circledR} (paclitaxel) and Herceptin{\circledR} (trastuzumab) are two milestones in the treatment of metastatic breast cancer. Accordingly it was feasible to study the combination of these two highly active drugs (with different toxicity profiles and mechanisms of action) in the treatment of metastatic breast cancer. In multicentric phase III trial performed in the US the combination of Herceptin with either taxane or anthracyclin was investigated. It was established that the combination of Herceptin with Taxol treatment significantly improves the overall response rate, increases the time to progression and the overall survival. These effects are more pronounced in patients characterized with HER/2 +++ overexpression. Based on these evidences the Herceptin{\circledR}- Taxol{\circledR} combined treatment protocol was introduced in Hungary for the treatment of Stage IV breast cancer patients. L{\'a}ng I. Possibilities and results with Herceptin{\circledR}-Taxol{\circledR} combination in the treatment of breast cancer. Hungarian Oncology 46:195-196, 2002.",
author = "I. L{\'a}ng",
year = "2002",
language = "Hungarian",
volume = "46",
pages = "195--196",
journal = "Magyar Onkologia",
issn = "0025-0244",
publisher = "Akademiai Kiado",
number = "2",

}

TY - JOUR

T1 - Lehetôségek és eredmények a Taxol®- Herceptin® kombináció alkalmazásával

AU - Láng, I.

PY - 2002

Y1 - 2002

N2 - Taxol® (paclitaxel) and Herceptin® (trastuzumab) are two milestones in the treatment of metastatic breast cancer. Accordingly it was feasible to study the combination of these two highly active drugs (with different toxicity profiles and mechanisms of action) in the treatment of metastatic breast cancer. In multicentric phase III trial performed in the US the combination of Herceptin with either taxane or anthracyclin was investigated. It was established that the combination of Herceptin with Taxol treatment significantly improves the overall response rate, increases the time to progression and the overall survival. These effects are more pronounced in patients characterized with HER/2 +++ overexpression. Based on these evidences the Herceptin®- Taxol® combined treatment protocol was introduced in Hungary for the treatment of Stage IV breast cancer patients. Láng I. Possibilities and results with Herceptin®-Taxol® combination in the treatment of breast cancer. Hungarian Oncology 46:195-196, 2002.

AB - Taxol® (paclitaxel) and Herceptin® (trastuzumab) are two milestones in the treatment of metastatic breast cancer. Accordingly it was feasible to study the combination of these two highly active drugs (with different toxicity profiles and mechanisms of action) in the treatment of metastatic breast cancer. In multicentric phase III trial performed in the US the combination of Herceptin with either taxane or anthracyclin was investigated. It was established that the combination of Herceptin with Taxol treatment significantly improves the overall response rate, increases the time to progression and the overall survival. These effects are more pronounced in patients characterized with HER/2 +++ overexpression. Based on these evidences the Herceptin®- Taxol® combined treatment protocol was introduced in Hungary for the treatment of Stage IV breast cancer patients. Láng I. Possibilities and results with Herceptin®-Taxol® combination in the treatment of breast cancer. Hungarian Oncology 46:195-196, 2002.

UR - http://www.scopus.com/inward/record.url?scp=0036355506&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036355506&partnerID=8YFLogxK

M3 - Article

C2 - 12202900

AN - SCOPUS:0036355506

VL - 46

SP - 195

EP - 196

JO - Magyar Onkologia

JF - Magyar Onkologia

SN - 0025-0244

IS - 2

ER -